Sera Prognostics Q2 2026: Revenue Climbs 76% YoY, Cash Runway Extended to 2029
SERA sits 29% above its 52-week low of $1.56.
Summary
Sera Prognostics' Q2 2026 revenue grew 76% year-over-year to $30K, while the company extended its cash runway to 2029 through a workforce reduction and reported $80.3M in cash and investments.
Key Events · Earnings and Guidance · SERA
-
Q2 Revenue Up 76% YoY
Revenue reached $30K in Q2 2026, up from $17K in Q2 2025, driven by the Illinois Medicaid mandate and a fourth partnership program.
-
Cash Runway Extended to 2029
The company's 18% workforce reduction is expected to generate $9.6M in annual cost savings, extending the cash runway through 2029. Cash and marketable securities totaled $80.3M as of June 30, 2026.
-
Net Loss Widens
Net loss was $9.1M for Q2 2026, compared to $8.0M in Q2 2025, reflecting increased commercialization spending and a $1.3M restructuring charge.
-
Illinois Medicaid Mandate
Illinois enacted legislation requiring Medicaid coverage for proteomic blood tests, covering approximately 50,000 annual Medicaid births, expanding access to the PreTRM test.
Analysis · SERA · Industrial Applications And Services
Sera Prognostics reported Q2 2026 revenue of $30K, up 76% from $17K in Q2 2025, driven by the Illinois Medicaid mandate and a fourth partnership program. The company's net loss widened to $9.1M from $8.0M a year ago, but a strategic 18% workforce reduction announced in May is expected to deliver $9.6M in annual cost savings, extending the cash runway through 2029. With $80.3M in cash and marketable securities, the company has sufficient liquidity to fund operations for at least the next 12 months. The filing also disclosed a new 10b5-1 trading plan by the General Counsel and the departure of the Chief Data Officer, who will transition to a consulting role.
At the time of this filing, SERA was trading at $2.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $79.1M. The 52-week trading range was $1.56 to $3.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.